518 related articles for article (PubMed ID: 15934499)
1. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for cancer: current and emerging concepts.
Jain RK
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy in cancer: a new era has begun.
Grothey A
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):5-6. PubMed ID: 16100843
[No Abstract] [Full Text] [Related]
4. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
Limaverde-Sousa G; Sternberg C; Ferreira CG
Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
[TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of antiangiogenic therapies.
Hudis CA
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
[TBL] [Abstract][Full Text] [Related]
8. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
9. [Antiangiogenic therapy for gastrointestinal tumors].
Lakatos G; Tulassay Z
Orv Hetil; 2008 Dec; 149(49):2317-24. PubMed ID: 19042183
[TBL] [Abstract][Full Text] [Related]
10. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
Cézé N; Lecomte T; Watier H
Med Sci (Paris); 2009 Dec; 25(12):1099-104. PubMed ID: 20035685
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
Cao Y; Liu Q
Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
[TBL] [Abstract][Full Text] [Related]
12. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic inhibitors: a new therapeutic strategy in oncology.
Gasparini G; Longo R; Toi M; Ferrara N
Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
[TBL] [Abstract][Full Text] [Related]
14. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
15. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
16. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
18. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Ellis LM; Rosen L; Gordon MS
Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
[TBL] [Abstract][Full Text] [Related]
19. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
20. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
